The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse relugolix in combination with estradiol and norethisterone acetate (Ryeqo®) from the basic health care package. This combination tablet is currently listed in the Medicine Reimbursement System (GVS) for the treatment of patients with severe menstrual bleeding due to uterine fibroids. If the Minister adopts our advice, this combination therapy will also be reimbursed for the treatment of endometriosis. Endometriosis is the presence and growth of uterine tissue outside the uterus.
Ryeqo® is intended for patients with the presence and growth of uterine tissue outside the uterus (endometriosis)
Relugolix in combination with estradiol and norethisterone acetate is the active substance. The brand name is (Ryeqo®). This therapy consists of a tablet that is ingested orally.
The combination therapy can be used in patients with endometriosis. In endometriosis, tissue that resembles the lining of the uterus grows outside the uterus, for example on the ovaries or fallopian tubes and further into the abdominal cavity. The marketing authorisation holder has applied for an expansion of the current reimbursement conditions for the treatment of endometriosis. The therapy is currently already listed in the GVS for the treatment of uterine fibroids.
Advice from the National Health Care Institute on the reimbursement of Ryeqo®
The National Health Care Institute advises the Minister of Health, Welfare and Sport to reimburse relugolix in combination with estradiol and norethisterone acetate (Ryeqo®) from the basic health care package. We recommend adjusting the List 2 conditions as follows:
For more information on the GVS and the Lists 1A, 1B and 2, see page ‘Reimbursement of extramural drugs (GVS)’.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, the personal expenses or whether you should pay a contribution, please ask your health insurance provider.
How did the advice come about?
The Minister of VWS asks the National Health Care Institute to make an assessment. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic healthcare package.
Explanation about the reimbursement of medicinal products
The combination preparation (Ryeqo®) is an extramural medicinal product. Extramural means: medicines for home use that can be obtained at the pharmacy with a prescription from a physician. They are only reimbursed from the basic health care package if they are listed in the GVS.